Literature DB >> 9675469

Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment.

C A Zurawski1, M Bardsley, B Beall, J A Elliott, R Facklam, B Schwartz, M M Farley.   

Abstract

Active, population-based surveillance for invasive group A streptococcal (GAS) disease was conducted in laboratories in metropolitan Atlanta from 1 January 1994 through 30 June 1995. Clinical and laboratory records were reviewed and isolates characterized. One hundred and eighty-three cases of invasive GAS disease were identified (annual incidence, 5.2 cases/100,000). The incidence was highest among blacks (9.7/100,000 per year; relative risk (RR), 1.92; confidence interval (CI), 1.69-2.19; P < .0001) and the elderly, particularly nursing home residents (RR, 13.66; CI, 7.07-26.40; P < .0001). The mean age of patients was 41.3 years (range, 0-95 years). Skin and soft-tissue infections were most common. Mortality was 14.4%; risk of death was significantly higher for patients with streptococcal toxic shock syndrome (STSS) (RR, 9.73; CI, 3.34-29; P = .0008) and individuals infected with M-type 1 (RR, 7.40; CI, 1.5-16; P = .0084). Fourteen percent of invasive GAS infections were STSS and 3% were necrotizing fasciitis. Invasive GAS disease was associated with varicella infection in children (RR, 12.19; CI, 5.58-26.62; P < .0001). M (or emm) types included M1 (16%), M12 (12%), and M3 (11%). Continued study of GAS disease is essential to further define risk factors and risk of secondary cases and to develop effective prevention strategies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9675469     DOI: 10.1086/514632

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  20 in total

1.  Multilocus sequence typing of Streptococcus pyogenes and the relationships between emm type and clone.

Authors:  M C Enright; B G Spratt; A Kalia; J H Cross; D E Bessen
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Therapeutic Approaches to Streptococcal Toxic Shock Syndrome.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

3.  Invasive group A streptococcal disease in Alberta, Canada (2000 to 2002).

Authors:  Gregory J Tyrrell; Marguerite Lovgren; Bertha Kress; Karen Grimsrud
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

4.  Flesh-eating disease: A note on necrotizing fasciitis.

Authors:  H D Davies
Journal:  Can J Infect Dis       Date:  2001-05

5.  Flesh-eating disease: A note on necrotizing fasciitis.

Authors:  H D Davies
Journal:  Paediatr Child Health       Date:  2001-05       Impact factor: 2.253

6.  Population-based surveillance of invasive group A streptococcal disease in British Columbia: 1996 to 1998.

Authors:  G L Bjorson; D W Scheifele; A Bell; A King
Journal:  Can J Infect Dis       Date:  2001-07

7.  Clinical and epidemiological aspects of invasive Streptococcus pyogenes infections in Denmark during 2003 and 2004.

Authors:  Bogdan Luca-Harari; Kim Ekelund; Mark van der Linden; Margit Staum-Kaltoft; Anette M Hammerum; Aftab Jasir
Journal:  J Clin Microbiol       Date:  2007-10-24       Impact factor: 5.948

8.  Invasive group a streptococcal infections, Israel.

Authors:  Allon E Moses; Sara Goldberg; Zinaida Korenman; Miriam Ravins; Emanuel Hanski; Mervyn Shapiro
Journal:  Emerg Infect Dis       Date:  2002-04       Impact factor: 6.883

9.  Prospective surveillance of invasive group a streptococcal disease, Fiji, 2005-2007.

Authors:  Andrew C Steer; Adam Jenney; Joseph Kado; Michael F Good; Michael Batzloff; Lepani Waqatakirewa; E Kim Mullholland; Jonathan R Carapetis
Journal:  Emerg Infect Dis       Date:  2009-02       Impact factor: 6.883

10.  Invasive group A streptococcal infection in older adults in long-term care facilities and the community, United States, 1998-2003.

Authors:  Michael C Thigpen; Chesley L Richards; Ruth Lynfield; Nancy L Barrett; Lee H Harrison; Kathryn E Arnold; Arthur Reingold; Nancy M Bennett; Allen S Craig; Ken Gershman; Paul R Cieslak; Paige Lewis; Carolyn M Greene; Bernard Beall; Chris A Van Beneden
Journal:  Emerg Infect Dis       Date:  2007-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.